Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia

Jennifer Kern Sliwa,1 Cynthia A Bossie,1 Dong-Jing Fu,1 Ibrahim Turkoz,2 Larry Alphs11Janssen Scientific Affairs LLC, 2Janssen Research and Development, LLC, Titusville, NJ, USABackground: A post hoc analysis from a multiphase trial with open-label transition and maintenance phases, a double-blind r...

Full description

Bibliographic Details
Main Authors:	Sliwa JK, Bossie CA, Fu D-J, Turkoz I, Alphs L
Format:	Article
Language:	English
Published:	Dove Medical Press 2012-08-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/long-term-tolerability-of-once-monthly-injectable-paliperidone-palmita-a10822

Similar Items

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
by: Alphs L, et al.
Published: (2013-03-01)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
by: O'Donnell A, et al.
Published: (2021-01-01)

Once-monthly paliperidone injection for the treatment of schizophrenia
by: Delia Bishara
Published: (2010-09-01)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
by: Li HF, et al.
Published: (2015-12-01)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
by: Si T, et al.
Published: (2019-06-01)

Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate
by: Charmi Patel, et al.
Published: (2019-11-01)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
by: Nash AI, et al.
Published: (2019-03-01)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
by: Emsley R, et al.
Published: (2017-08-01)

Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial
by: Ma Yi-Wen, et al.
Published: (2011-04-01)

Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia
by: Dominic Pilon, et al.
Published: (2017-06-01)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
by: Mathews M, et al.
Published: (2019-05-01)

Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults
by: Kim S, et al.
Published: (2012-07-01)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
by: Li H, et al.
Published: (2018-04-01)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
by: Mathews M, et al.
Published: (2018-10-01)

Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial
by: Fu Dong-Jing, et al.
Published: (2011-05-01)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
by: Gattaz WF, et al.
Published: (2020-09-01)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
by: Samtani MN, et al.
Published: (2013-05-01)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
by: Zhang F, et al.
Published: (2015-03-01)

Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis
by: Charmi Patel, MPH, RN, et al.
Published: (2020-01-01)

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
by: Christophe Sapin, et al.
Published: (2016-09-01)

Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability – a review
by: González-Rodríguez A, et al.
Published: (2015-05-01)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
by: Li G, et al.
Published: (2021-10-01)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
by: Hodgson RE
Published: (2019-08-01)

Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
by: Steven G Potkin, et al.
Published: (2017-01-01)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
by: Lopez A, et al.
Published: (2019-02-01)

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
by: Einarson Thomas R, et al.
Published: (2012-07-01)

Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
by: Mahlich J, et al.
Published: (2015-05-01)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
by: Takada R, et al.
Published: (2018-10-01)

Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia
by: Juan J. Fernández-Miranda, et al.
Published: (2021-04-01)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
by: Hodgson RE
Published: (2019-09-01)

Correction: Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
by: PLOS ONE Staff
Published: (2017-01-01)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
by: Li N, et al.
Published: (2018-03-01)

A case report of pregnancy and paliperidone palmitate 3‐monthly long‐acting injection
by: Rita deAzevedo Avelar, et al.
Published: (2020-12-01)

Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report
by: Hassan Mirza, et al.
Published: (2018-09-01)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
by: Ibrahim Turkoz, et al.
Published: (2008-08-01)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
by: Emsley R, et al.
Published: (2018-01-01)

Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate
by: Rebekka Lencer, et al.
Published: (2021-05-01)

Manic Symptoms during a Switch from Paliperidone ER to Paliperidone Palmitate in a Patient with Schizophrenia
by: Kadir Demirci, et al.
Published: (2015-01-01)

Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia
by: Carpiniello B, et al.
Published: (2016-05-01)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
by: Brasso C, et al.
Published: (2017-11-01)